title: N-acetylcysteine prevents endoplasmic reticulum stress elicited in macrophages by serum albumin drawn from chronic kidney disease rats and selectively affects lipid transporters, ABCA-1 and ABCG-1.
abstract: In chronic kidney disease (CKD) nontraditional risk factors, such as oxidative stress and advanced glycation end products (AGE) contribute to cardiovascular disease. Particularly, disturbances in reverse cholesterol transport favor the development of atherosclerosis. We analyzed the influence of N-acetylcysteine (NAC) in CKD rats on plasma concentration of lipid peroxides (TBARS) and AGE and on the impact of serum albumin in the development of macrophage endoplasmic reticulum stress (ERS) and cholesterol efflux, namely apo A-I and HDL2-mediated cholesterol removal and ABCA-1 and ABCG-1 protein level. CKD was induced by 5/6 nephrectomy in 2-month old male Wistar rats. Controls (Sham) were false operated. Animals were treated or not with NAC (600 mg/L of water). After 60 days serum albumin was isolated by FPLC and purified by alcoholic extraction. J774 macrophages were incubated with serum albumin (1 mg/mL; 18 h) from all groups, and the expression of ERS markers (protein disulfide isomerase - PDI, Grp78 and Grp94), ABCA-1 and ABCG-1 determined by immunoblot. HDL2 or apo A-I were used for cholesterol efflux assays. Protein and lipid composition of total HDL from Sham and CKD was determined and these particles tested on their abilities to accept cell cholesterol. Comparisons were done by one-way ANOVA and Newman Keuls post test. After 60 days of CKD, body weight was 10% lower in CKD compared to Sham (p < 0.01). This was prevented by NAC. Urea, creatinine, total cholesterol (TC), triglycerides (TG) (mg/dL), proteinuria (mg/24 h) (Sham, n = 31; Sham + NAC, n = 20; CKD, n = 74; CKD + NAC, n = 32), total AGE and pentosidine (n = 8; fluorescence arbitrary unit) and TBARS (n = 7; nmoL/mL) were higher in CKD (122 ± 8; 0.9 ± 0.07; 151 ± 6; 83 ± 4; 46 ± 2.5; 32,620 ± 673; 16,700 ± 1,370; 6.6 ± 0.5, respectively) and in CKD + NAC (91.4 ± 5; 0.6 ± 0.02; 126 ± 7.5; 73 ± 6; 51 ± 3.5; 24,720 ± 1,114; 10,080 ± 748; 4.5 ± 0.5, respectively) in comparison to Sham (41 ± 0.9; 0.4 ± 0.03; 76 ± 2.7; 51.5 ± 3; 14 ± 0.9; 21,750 ± 960; 5,314 ± 129; 2.0 ± 0.2, respectively; p < 0.001) and Sham + NAC (40 ± 0.9; 0.3 ± 0.02; 76 ± 2.6; 68 ± 4; 18.4 ± 1.5; 20,040 ± 700; 5,050 ± 267; 1.8 ± 0.2, respectively; p < 0.001). TC, urea, creatinine, total AGE, pentosidine and TBARS were respectively, 17%, 25%, 33%, 24%, 40% and 28% (p < 0.01) lower in CKD + NAC, than in CKD. Glycemia was higher in Sham + NAC (107 ± 4.6) and CKD + NAC (107 ± 2.6) than in Sham (96 ± 1.8; p < 0.05) and CKD (98 ± 1.6; p < 0.01), respectively. In macrophages (n = 6), CKD albumin increased PDI (3 and 6 times, p < 0.01) and Grp94 (66% and 80%, p < 0.01) in comparison to Sham and CKD + NAC-albumin treated cells, respectively. ABCA-1 expression was lower (87% and 70%, p < 0.001) in macrophage treated with Sham + NAC and CKD albumin respectively in comparison to Sham albumin; ABCG-1 was higher (4 and 7 times, p < 0.001) in macrophages treated with Sham + NAC and CKD + NAC albumin, respectively in comparison to Sham and CKD albumin. Apo A-I mediated cholesterol efflux was lower (59% and 70%, p < 0.0001) in macrophage treated with Sham + NAC and CKD albumin respectively in comparison to Sham albumin, however, the HDL2 mediated cholesterol efflux was higher (54% and 25%, p < 0.0001) in macrophage treated with Sham + NAC albumin, in comparison to Sham and CKD + NAC albumin, respectively. CKD-HDL was enriched in total protein and lipids compared to Sham-HDL but preserved its capacity to remove cholesterol from macrophages. NAC reduces plasma lipid peroxidation and AGE and abrogates ERS induced by CKD-albumin. Despite diminishing ABCA-1, NAC increases ABCG-1 that counteracts the reduction in apo A-I-mediated cholesterol efflux. NAC may contribute to attenuate the deleterious effects of CKD-albumin on lipid accumulation in macrophages helping to prevent atherogenesis in CKD.
authors.affiliation: Lipids Laboratory (LIM 10), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Juliana T
authors.initials: JT
authors.lastname: Machado
authors.affiliation: Lipids Laboratory (LIM 10), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Rodrigo T
authors.initials: RT
authors.lastname: Iborra
authors.affiliation: Lipids Laboratory (LIM 10), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Fernanda B
authors.initials: FB
authors.lastname: Fusco
authors.affiliation: Lipids Laboratory (LIM 10), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Gabriela
authors.initials: G
authors.lastname: Castilho
authors.affiliation: Lipids Laboratory (LIM 10), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Raphael S
authors.initials: RS
authors.lastname: Pinto
authors.affiliation: Lipids Laboratory (LIM 10), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Adriana
authors.initials: A
authors.lastname: Machado-Lima
authors.affiliation: Lipids Laboratory (LIM 10), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Edna R
authors.initials: ER
authors.lastname: Nakandakare
authors.affiliation: Laboratory of Basic Science (LIM 12), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Antonio C
authors.initials: AC
authors.lastname: Seguro
authors.affiliation: Laboratory of Basic Science (LIM 12), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Maria H
authors.initials: MH
authors.lastname: Shimizu
authors.affiliation: Lipids Laboratory (LIM 10), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil.
authors.forename: Sergio
authors.initials: S
authors.lastname: Catanozi
authors.affiliation: Lipids Laboratory (LIM 10), Faculty of Medical Sciences, University of São Paulo Medical School, São Paulo, SP, Brazil. Electronic address: mpassere@usp.br.
authors.forename: Marisa
authors.initials: M
authors.lastname: Passarelli
mesh_terms: D064286:ATP Binding Cassette Transporter 1 / Q000378:metabolism; D000070998:ATP Binding Cassette Transporter, Subfamily G, Member 1; D018528:ATP-Binding Cassette Transporters / Q000378:metabolism; D000111:Acetylcysteine / Q000378:metabolism*; D000418:Albumins / Q000378:metabolism; D000818:Animals; D016632:Apolipoprotein A-I / Q000378:metabolism*; D001692:Biological Transport; D001835:Body Weight; D002784:Cholesterol / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004721:Endoplasmic Reticulum / Q000378:metabolism*; D000091342:Endoplasmic Reticulum Chaperone BiP; D059865:Endoplasmic Reticulum Stress; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D015227:Lipid Peroxidation; D008055:Lipids / Q000737:chemistry*; D008074:Lipoproteins / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D051379:Mice; D009392:Nephrectomy; D010100:Oxygen / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000378:metabolism
chemical_list: D064286:ATP Binding Cassette Transporter 1; D000070998:ATP Binding Cassette Transporter, Subfamily G, Member 1; D018528:ATP-Binding Cassette Transporters; D000111:Acetylcysteine; D000418:Albumins; D016632:Apolipoprotein A-I; D002784:Cholesterol; D000091342:Endoplasmic Reticulum Chaperone BiP; D008055:Lipids; D008074:Lipoproteins; D010100:Oxygen; D012709:Serum Albumin; C577833:Abca1 protein, mouse; C577834:Abca1 protein, rat; C487540:ABCG1 protein, mouse; C559724:Abcg1 protein, rat; C000717248:Hspa5 protein, mouse
keywords: Albumin; Atherosclerosis; Chronic kidney disease; N-acetylcysteine; Reverse cholesterol transport